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Elevated levels of adrenocorticotrophic hormone (ACTH) mobilize
granulocytes from bone marrow into the blood, although these neu-
trophils are refractory to a full migratory response into inflamed
tissues. Here, we investigated the dependence of glucocorticoid re-
ceptor activation and glucocorticoid-regulated protein annexin A1
(ANXA1) on ACTH-induced neutrophilia and the phenotype of blood
neutrophil after ACTH injection, focusing on adhesion molecule
expressions and locomotion properties. ACTH injection (5 g ip, 4 h)
induced neutrophilia in wild-type (WT) mice and did not alter the
elevated numbers of neutrophils in RU-38486 (RU)-pretreated or
ANXA1/ mice injected with ACTH. Neutrophils from WT ACTH-
treated mice presented higher expression of Ly6GANXA1high,
CD18high, CD62Lhigh, CD49high, CXCR4high, and formyl-peptide re-
ceptor 1 (FPR1low) than those observed in RU-pretreated or
ANXA1/ mice. The membrane phenotype of neutrophils collected
from WT ACTH-treated mice was paralleled by elevated fractions of
rolling and adherent leukocytes to the cremaster postcapillary venules
together with impaired neutrophil migration into inflamed air pouches
in vivo and in vitro reduced formyl-methionyl-leucyl-phenylalanine
(fMLP) or stromal-derived factor-1 (SDF-1)-induced chemotaxis. In
an 18-h senescence protocol, neutrophils from WT ACTH-treated
mice had a higher proportion of ANXAVlow/CXCR4low, and they
were less phagocytosed by peritoneal macrophages. We conclude that
alterations on HPA axis affect the pattern of membrane receptors in
circulating neutrophils, which may lead to different neutrophil phe-
notypes in the blood. Moreover, ACTH actions render circulating
neutrophils to a phenotype with early reactivity, such as in vivo
leukocyte-endothelial interactions, but with impaired locomotion and
clearance.
hypothalamic-pituitary-adrenal axis; chemokine (C-X-C motif) recep-
tor 4; adhesion molecules; chemotaxis; intravital microscopy
THE TRAFFIC OF NEUTROPHILS IN BODY COMPARTMENTS is pivotal to
homeostasis. A continuous delivery of mature granulocytes
from the bone marrow yields about 1011 and 107 neutrophils
each day into the blood in humans and mice, respectively (19,
31). Although recent data have suggested that a specific pop-
ulation of neutrophils may circulate for longer periods of time
(42), the majority of these cells circulate for 6–8 h, becoming
senescent and migrating into different terminal tissues (19).
The bone marrow blood trafficking of neutrophils is mediated
by membrane adhesion molecule expression on neutrophils,
sinusoids, and postcapillary venules. Although the role of
CD62L, CD18, and CD49d expressed on neutrophils has been
proposed in bone marrow/blood traffic, the data are controver-
sial (2, 3, 8). In contrast, it is well established that expression
of chemokine (C-X-C motif) receptor 4 (CXCR4) mediates the
maintenance of mature granulocytes in the bone marrow as
well as the homing of circulating senescent neutrophils back to
the bone marrow.
The mature pool of granulocytes in the bone marrow is
CXCR4high, which is decreased during the delivery process
into the blood (19). In the circulation, senescent neutrophils
undergo progressive CXCR4 expression with increased re-
sponsiveness to bone marrow stromal-derived factor-1
(SDF-1), which drives CXCR4 senescent neutrophils
back to the bone marrow to be cleared by local macrophages
(19, 54). The relevance of the CXCR4-SDF-1 axis in
neutrophil trafficking is evident in CXCR4-knockout mice
(14) and individuals with WHIM (warts, hypogammaglobu-
linemia, infections and myelokathexis) congenital syn-
drome, which is caused by persistent CXCR4 expression in
bone marrow neutrophils. The resulting severe neutropenia
detected in WHIM subjects reflects the retention of mature
granulocytes together with augmented apoptosis in the bone
marrow (1, 11, 23, 59). In agreement with this model,
treatment with the CXCR4 antagonist plerixafor induces
neutrophilia in humans and mice (10, 33).
The molecular mechanisms involved in the delivery of
mature neutrophils into the blood during physiological or stress
conditions are complex and not completely understood. None-
theless, strong evidence has supported the involvement of the
hypothalamic-pituitary-adrenal (HPA) axis. Chemical media-
tors secreted at the site of inflammation reach the hypothala-
mus and pituitary tissues, leading to the release of corticotro-
pin-releasing hormone and adrenocorticotrophic hormone
(ACTH), respectively. ACTH stimulates peripheral tissues to
release glucocorticoids, which will halt the acute inflammatory
process (4, 5, 16, 24, 25, 39, 49). Nevertheless, ACTH might
exert direct anti-inflammatory activities in an arthritis-induced
model in rats (20) by acting selectively on tissual melanocor-
tin-3 receptor, inhibiting proinflammatory mediator release and
neutrophil migration (21, 22, 38).
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Neutrophilia caused by stimulation of the HPA axis is
supposedly centered on endogenous glucocorticoids, as the
platelet-activating factor-induced neutrophilia was accom-
plished by elevated levels of corticosterone and abolished in
mice treated with RU-38486, a cytosolic glucocorticoid recep-
tor antagonist (25, 39). A downstream effector of glucocorti-
coids for the control of neutrophil reactivity is the protein
annexin A1 (ANXA1) (40), yet the role of this protein on
ACTH-induced neutrophil mobilization has not been shown.
HPA activation-induced neutrophilia is dependent mainly on
the mobilization of the bone marrow pool of mature granulo-
cytes (27, 32, 47). Interestingly, neutrophils that migrate into
the blood following HPA activation during ongoing inflamma-
tion present a lower ability to migrate into inflamed tissues (27,
47, 56). Therefore, we hypothesize that the population of blood
neutrophils after HPA activation presents different and possi-
bly unique phenotypes that support their rapid activity in the
blood, with moderating effects on the extent of tissue-specific
migration, and subsequent removal by clearance tissues. To
challenge this hypothesis, we investigated the profile of neu-
trophils in the blood after administration of ACTH, focusing on
membrane receptors involved in the migratory processes to
inflamed and clearance tissues.
MATERIALS AND METHODS
Animals
Male wild-type (WT) and ANXA1-null (ANXA1/) (24) 5- to
6-wk-old BALB/c mice were obtained from the Animal House at the
School of Pharmaceutical Sciences, University of São Paulo (Brazil).
Chow and water were available ad libitum. During the experimental
procedures, the animals were anesthetized with ketamine-xylazine
(77:7 mg/kg) to avoid any stress conditions. All animal procedures
were performed according to protocols approved by the Ethics Com-
mittee on Animal Use of the School of Pharmaceutical Sciences,
University of São Paulo, (CEUA/FCF/285), for the proper use and
care of experimental animals.
Pharmacological Treatments
The glucocorticoid receptor antagonist mifepristone (RU-38486, 10
mg/kg; Sigma, St. Louis, MO) was dissolved in carboxymethyl
cellulose (2 mg/ml), polysorbate 80 (50 l/ml), ethanol (40 l/ml),
and phosphate-buffered saline (PBS; pH 7.2–7.4) and administered
intraperitoneally (ip) 24 and 2 h before ACTH or vehicle (PBS).
ACTH (Synacthen Depot; Novartis, Basel, Switzerland) was admin-
istrated at 5 g/animal (ip), and experiments were carried out 4 h
later. Control animals received the same volume of the vehicle used to
dissolve the drugs via the same route.
Hematological Parameters
Blood. Animals were anesthetized and whole blood samples ob-
tained via abdominal aorta punctures using EDTA (2 mg/ml; Sigma).
Total cells were quantified using a Neubauer chamber. Differential
leukocyte counts were performed on blood smears stained with May
Grumwald-Giemsa solution (Sigma).
Bone marrow. Bone marrow cells were obtained by flushing the
femoral cavity with 2 ml of McCoy’s 5A medium (Sigma). The
number of total cells was quantified in a Neubauer chamber. Differ-
ential counts were performed on the basis of 500 cells/slide smear
stained with May Grumwald-Giemsa.
Enzyme-Linked Immunosorbent Assay
Corticosterone (Cayman, Ann Arbor, MI) levels were quantified in
the plasma obtained from the circulating blood of animals. Granulo-
cyte colony-stimulating factor (G-CSF; R & D Systems, Minneapolis,
MN) concentrations were determined in the supernatant of bone
marrow macrophage culture during the phagocytosis of senescent
neutrophils, as described in Preparation of Senescent Neutrophils and
In Vitro Senescent Neutrophil Phagocytosis by Bone Marrow Macro-
phages. Samples obtained from each experiment were analysed in
duplicate, and experiments were carried out according to the manu-
facturers’ protocols.
Flow Cytometry
Leukocytes were isolated from blood collected from the abdominal
aorta or from the bone marrow to evaluate Ly6G, CXCR4, CD18,
CD49d, CD62L, and formyl peptide receptor-1 (FPR-1) expressions.
In brief, erythrocyte lysis was performed using an ammonium chloride
solution (0.13 M) in blood samples, and leukocytes were recovered
after washing with PBS. Leukocytes (1  106) from blood or bone
marrow were incubated for 20 min at 4°C in the dark with 100 l of
monoclonal antibody against Ly6G (PECy7-conjugated rat anti-
mouse; 50 g/ml), CXCR4 (PE-conjugated rat anti-mouse CXCR4;
50 g/ml), CD18 (FITC-conjugated rat anti-mouse CD18; 50 g/ml),
CD49d (PE-conjugated rat anti-mouse CD49d; 50 g/ml), CD62L
(PE-conjugated rat anti-mouse CD62L,; 50 g/ml), or FPR-1 (FITC-
conjugated rabbit anti-mouse FPR1). All antibodies were diluted
1:100. Immediately after incubations, cells were analysed on a FACS
Canto flow cytometer (Becton and Dickinson, San Jose, CA). Data
from 10,000 cells were obtained, and results were expressed as the
percentage of positive cells and mean of fluorescence intensity (MFI).
Ly6G, CXCR4, and adhesion molecule antibodies were purchased
from BD PharMingen Technical, and FPR-1 was purchased from from
Abcam (London, UK).
In vivo neutrophil migration
Animals were anesthetized, and 3 ml of sterile air was injected
subcutaneously into the dorsal region. After 6 days, the pouch was
refilled with 3 ml of air. On the 10th day following the first air
injection, animals were treated with ACTH (5 g/animal) or vehicle.
After 4 h, LPS from E. coli (serotype 026:B6, 100 g/ml PBS, 2
ml/animal; Sigma) was injected directly into the pouches. Four hours
later, the animals were reanesthetized and euthanized. The pouches
were washed with 3 ml of ice-cold PBS, and the total leukocyte
number was determined using a Neubauer chamber.
In Vitro Neutrophil Chemotaxis Assay
Samples from whole blood were obtained, and neutrophils were
separated by a modified Percoll method (15). A Percoll gradient was
made by slowly adding 3 ml of 70% Percoll solution above 3 ml of
60% Percoll solution (Sigma), both of which diluted in Hanks’
balanced salt solution (HBSS; Gibco, Grand Island, NY). Subse-
quently, 3 ml of whole blood was added slowly above the Percoll
gradient and centrifuged at 500 g for 35 min at 22°C, with accelera-
tion/braking of 2 m/s2. After centrifugation, a halo between the 70 and
60% Percoll solutions containing the neutrophils was observed and
collected. Then, the neutrophils were washed with HBSS by centrif-
ugation at 400 g for 10 min at 22°C. After washing, neutrophils were
resuspended at 2 105 cells/ml in HBSS supplemented with Ca2. In
the next step, 25 l of cell suspension from blood was loaded into the
top well of a commercially available Neuroprobe ChemoTx-101-8
96-well plate equipped with an 8-m pore size fillter (Neuroprobe;
Leamington Spa). As a chemoattractant, formyl-methionyl-leucyl-
phenylalanine (fMLP; 106 M) (Sigma) was added in the bottom
well. The chemotaxis assay with neutrophils from the blood was
incubated for 2 h, and a cell suspension from the bone marrow was
incubated for 1 h at 37°C and 5% CO2. Migrated neutrophils from the
blood were counted using a Neubauer chamber.
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Preparation of Senescent Neutrophils
To evaluate the effect of ACTH on aging, neutrophils were isolated
from peripheral blood (see Blood) of male Balb/C mice treated with
ACTH (5 g·animal1·4 h1) or vehicle by Percoll gradient (15).
Neutrophils (1  106 cells/ml) were incubated for 18 h in RPMI 1640
medium (Sigma, St. Louis, MO) with 10% FBS (Vitrocell, Campinas,
Sao Paulo, Brazil) at 37°C and 5% CO2. After the incubation period,
neutrophils with a senescent profile (7) were characterized by
CXCR4/annexin V labeling (ANXV APC conjugated and CXCR4 PE
conjugated, 50 g/ml; BD PharMingen). Immediately after incuba-
tion, cells were analyzed on a FACS Canto flow cytometer (Becton
and Dickinson). Data from 10,000 cells were obtained, and results
were expressed as the percentage of positive cells and the mean of
MFI.
In Vitro Senescent Neutrophil Phagocytosis By Bone Marrow
Macrophages
After bone marrow cells were obtained, as described in Bone
marrow, 1  107 cells were incubated in a 24-well cell culture plate
prepared previously by placing a sterile 13-mm round glass coverslip
into each well containing 500 l RPMI 1640 with 10% of FBS and
incubating for 2 h at 37°C and 5% CO2. After incubation, nonadherent
cells were removed by three washes with ice-cold PBS. As described
in Preparation of Senescent Neutrophils, mouse apoptotic neutrophils
(1  106 cells/well) were added to bone marrow macrophages and
incubated for 1 h at 37°C and 5% CO2. Noningested cells were
removed by three washes with PBS, and phagocytosis was assayed on
a coverslip stained with May Grumwald-Giemsa dye. For each ex-
periment, the number of macrophages containing one or more neu-
trophils in at least five fields (minimum of 400 cells counted) was
expressed as a percentage of the total number of macrophages (7).
Intravital Microscopy
Mice received saline or ACTH (5 g/animal) and 4 h later under-
went an intravital microscopy study. The animals were anesthetized,
the cremaster muscle was surgically exteriorized, and animals were
maintained on a special board that was thermostatically controlled at
37°C, which included a transparent platform on which the tissue was
placed. The preparation was kept moist and warmed by irrigating the
tissue with a warmed (37°C) Ringer-Locke solution (pH 7.2–7.4). The
rate of solution outflow onto the exposed tissue was controlled to keep
the preparation in continuous contact with a film of the solution.
Trans-illuminated images were captured with a video camera and
simultaneously transmitted to a computer. Interaction between leuko-
cytes and vessel walls was analyzed by determining the number of
rolling and adherent leukocytes on the postcapillary venule wall
(20–30 m in diameter, 200 m in length) of the cremaster muscle.
Leukocytes moving in the periphery of the axial stream in contact
with the endothelium were considered to be rollers, and their number
was determined in 5-min periods. The number of leukocytes adhered
to the endothelial wall was determined in the same vascular segment
at the end of 5 min. Data were considered the average for three fields
in each animal (18).
ANXA1 Expression in Neutrophils from Bone Marrow and Blood by
Immunofluorescence
Blood and bone marrow leukocytes were prepared on 0.1% gela-
tine-coated glass coverslips. After 30 min, adherent cells were fixed in
4% paraformaldehyde for 15 min, permeabilized with 0.4% Tween-
20-PBS for 15 min, blocked with 3% goat serum (Abcam) containing
0.1% bovine serum albumin (Sigma-Aldrich) in PBS for 1 h, and then
incubated with rabbit polyclonal anti-ANXA1 antibody (1:300; Invit-
rogen, Zymed Laboratories, Carlsbad, CA) in PBS containing 1.5%
goat serum overnight at 4°C. After three rinses with PBS, the samples
were incubated with PE-conjugated goat anti-rabbit secondary anti-
body (1:100; Abcam) in PBS containing 1.5% goat serum for 1 h at
room temperature in the dark. The slides were then washed in PBS
and stained with 300 nM 4=,6-diamidino-2-phenylindole (DAPI; Sig-
ma-Aldrich) for 10 min, followed by three rinses with PBS. After
mounting with fluorescent mounting medium, the slides were ob-
served under a Zeiss-Axioskop 2 fluorescence microscope (Carl Zeiss
Fig. 1. Plasma corticosterone levels. Balb/c mice were pretreated with RU-
38486 (RU; 10 mg/kg ip) 24 and 2 h before ip injection of ACTH or vehicle
injection (5 g/animal ip). Annexin A1 (ANXA1)/ animals were treated
with ACTH or vehicle injection (5 g/animal ip). After 4 h, peripheral blood
was collected from the abdominal aorta. Results are expressed as means  SE
of 6 animals in each group. Statistical analysis was performed using ANOVA,
followed by Tukey’s test. *P  0.05, **P  0.01, and ***P  0.001 vs.
respective control; #P  0.05 vs. wild-type (WT) vehicle-treated mice; §P 
0.05 vs WT ACTH-treated animals. KO, knockout.
A
B
Fig. 2. ACTH effects on the number of neutrophils in the bone marrow and
blood. Balb/c WT mice pretreated or not with RU (10 mg/kg ip, 24 and 2 h
before) or ANXA1/ received peritoneal injection of ACTH (5 g/animal) or
vehicle. Four hours later, animals were anesthetized and peripheral blood from
abdominal aorta and medullar perfusate collected. No. of mature granulocytes
in the bone marrow (A) and neutrophils in the peripheral blood (B). Statistical
analysis was performed using ANOVA, followed by Tukey’s test. Data are
expressed as means  SE. Mean values obtained in 6 animals for each group.
*P  0.05 and ***P  0.001 vs. WT vehicle; #P  0.05 vs. KO vehicle-
treated animals; **P  0.01 vs. WT ACTH-treated animals.
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Meditec, San Antonio, TX). Densitometric analysis for the ANXA1
immunostaining on neutrophils was performed to an arbitrary scale
ranging from 0 to 255 using AxioVision software (Carl Zeiss). Images
represent the overlap of DAPI plus ANXA1 staining from bone
marrow and blood neutrophils.
Statistical Analysis
Means  SE of data are presented and were compared using
Student’s t-test or analysis of variance, followed by Tukey multiple
comparison test, with a significant probability of 0.05.
RESULTS
In Vivo ACTH Injection mobilizes ANXA1, CD62L,
CD18, CD49d, and CXCR4 Neutrophils, Depending on
Glucocorticoid Receptor Activation and ANXA1
In vivo treatment with ACTH significantly increased the
concentration of corticosterone in the plasma of animals treated
with vehicle or RU-38486 as well as ANXA1/ mice. How-
ever, ANXA1/ animals presented lower corticosterone lev-
els than those found in WT animals either in basal conditions
or after ACTH administration (Fig. 1), corroborating in vitro
data about the action of ANXA1 on cells of the HPA axis (29,
36, 41). In addition, the ACTH-induced enhancement of
plasma corticosterone levels in RU-38486-treated mice was
lower than that observed in vehicle-treated mice (Fig. 1), which
reinforces the role of glucocorticoid actions on HPA axis (30,
41, 55) and shows the genomic pathway on the effect. Four
hours after ACTH injection, mature neutrophils were mobi-
lized from the bone marrow into the blood, as detected by the
reduced numbers of mature granulocytes in the bone marrow
(Fig. 2A) and the parallel increase in circulating neutrophils
(Fig. 2B). Pretreatment of mice with RU-38486 did not modify
the number of granulocytes in the bone marrow but caused
neutrophilia (Fig. 2, A and B); in the presence of RU-38486
pretreatment, ACTH injection did not modify these profiles of
neutrophils in both compartments (Fig. 2, A and B). In addition,
ANXA1/ mice presented an elevated number of neutrophils
in both bone marrow and blood, and ACTH treatment reduced
the number of neutrophils in the bone marrow but failed to
modify the number of cells in the blood (Fig. 2, A and B).
To characterize the phenotype of blood neutrophils, expres-
sions of membrane receptors involved in adhesion and migra-
tory processes were quantified. ACTH injection caused mobi-
lization of ANXA1high from bone marrow into blood, as
reduced or elevated numbers of ANXA1high neutrophils were
detected in the bone marrow and blood, respectively (Fig. 3).
In addition, the population of neutrophils in the blood 4 h after
ACTH injection was Ly6GCD18high, CD49dhigh, CD62Lhigh,
and CXCR4high (Fig. 4, A–H). Neutrophils collected from
RU-38486-treated mice or ANXA1/ did not present altera-
tions on CD18, CD49d, and CXCR4 expressions compared
with age-matched WT mice; in these animals, ACTH treatment
A B
C D
Fig. 3. ANXA1 expression in neutrophils from
bone marrow and peripheral blood in ACTH-
treated mice. Balb/c mice were treated with
ACTH or vehicle (5 g/animal ip, 4 h before
the experiment). Representative images and
densitometric analysis of bone marrow (A and
B) and peripheral blood neutrophils (C and D)
labeled for ANXA1. 4=,6-Diamidino-2-phe-
nylindole (DAPI) nuclear counterstain con-
firmed neutrophil morphology. Images repre-
sent the overlap of DAPI plus ANXA1 staining.
Statistical analysis was performed using Stu-
dent’s t-test. Data are expressed as means SE
of arbitrary units (n 	 6 animals/group).
***P  0.001 vs. vehicle.
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Fig. 4. Adhesion molecules and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in neutrophils obtained from peripheral blood of WT and ANXA1/
mice treated with ACTH. Balb/c mice pretreated with RU (10 mg/kg ip, 24 and 2 h before the experiment) or ANXA1/ mice received peritoneal injection
of ACTH (5 g/animal ip) or vehicle. Animals were anesthetized, and peripheral blood was collected from the abdominal aorta. Adhesion molecules and CXCR4
expressions were quantified by flow cytometry. A and B: CD18 expression. C and D: CD49d expression. E and F: CD62L expression. G and H: CXCR4
expression. Results are expressed as means  SE of 6 animals in each group. Statistical analysis was performed using ANOVA, followed by Tukey’s test. *P 
0.05, **P  0.01, and ***P  0.001 vs. vehicle; #P  0.05 and ###P  0.001 vs. WT ACTH-treated animals. MFI, mean of fluoresence intensity.
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failed to elevate the expression of these molecules (Fig. 4,
A–D, G, and H). Analysis of the histograms for each receptor
indicates that ACTH treatment leads to specific population of
neutrophils stained with CD18, CD49d, and CXCR4 (Fig. 4 B,
D, and H). On the other hand, neutrophils stained with CD62L
were detected in ACTH or RU-38386-treated mice and in
ANXA1/ animals (Fig. 4F).
In agreement with previous studies (4, 5, 9), enhanced
expressions of CD62L on neutrophils from RU-38486 or
ANXA1/ mice could be quantified, and this was efficiently
reversed by ACTH treatment (Fig. 4, E and F).
In vivo ACTH Injection Enhances Leukocyte-Endothelium
Interactions in the Microvasculature
To evaluate the behavior of neutrophils in the circulation
after ACTH administration, in vivo observations of the micro-
circulation of the cremaster muscle were performed by intra-
vital microscopy. In noninflammatory conditions, ACTH-
treated animals showed an increased number of rollers and
adherent leukocytes to the vascular endothelium compared
with vehicle-treated animals (Fig. 5).
In Vivo ACTH Injection Impairs Chemotaxis of Neutrophils
Into Inflamed and Clearance Tissues
Inflammation induced by the injection of LPS into the
subcutaneous tissue was characterized by reduced numbers of
neutrophils in the exudate collected from ACTH-treated ani-
mals compared with vehicle-treated mice (Fig. 6A).
Moreover, in vitro chemotatic response to fMLP was re-
duced if neutrophils were purified from ACTH-treated animals
(Fig. 6B), which may be dependent on the reduced expression
of FPR1 (Fig. 6C).
In addition, blood neutrophils obtained from ACTH-treated
mice also presented reduced chemotactic response to SDF-1
(Fig. 7A), even if they were CXCR4high (Fig. 4G). These data
infer that CXCR4high neutrophils could remain in the circula-
tion after ACTH injection, and lower numbers of CXCR4high
cells would be in the bone marrow. Therefore, subsequent flow
cytometry was carried out in bone marrow cells to investigate
the fate of CXCR4high neutrophils. Data obtained showed that
the percentage of CXCR4high bone marrow neutrophils (Fig.
7B) and levels of CXCR4 per cell (Fig. 7C) were equivalent in
ACTH- or vehicle-treated animals.B
A
Fig. 5. Effect of ACTH administration on leukocyte-endothelial interactions
after ACTH treatment. Balb/c WT mice were treated with ACTH (5 g/animal
ip) or vehicle 4 h before exposure of cremaster muscle to intravital microscopy
study. A: no. of leukocytes in rolling process. B: no. of leukocytes adhering to
the endothelium. Results are expressed as means  SE of 6 animals in each
group. Statistical analysis was performed using Student’s t-test. *P 0.05 and
**P  0.01 vs. corresponding vehicle.
B
C
A
Fig. 6. Effect of ACTH administration on in vivo and in vitro neutrophil
migration and formyl peptide receptor-1 (FPR-1) expression. Balb/c WT mice
were treated with ACTH (5 g/animal ip) or vehicle 4 h before the experiment.
A: total no. of leukocytes migrating into the air pouch induced by LPS (100
g/ml, 2 ml/animal). B: in vitro chemotaxis of neutrophils obtained from
peripheral blood in response to formyl-methionyl-leucyl-phenylalanine
(fMLP). C: FPR-1 expression on neutrophils obtained from peripheral blood.
Results are expressed as means  SE of 6 animals in each group. Statistical
analysis was performed using Student’s t-test and ANOVA, followed by
Tukey’s test. *P  0.05 and **P  0.01 vs. corresponding vehicle.
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In Vivo ACTH Reduces Neutrophil Senescence and their
Phagocytosis by Bone Marrow Macrophages
According to the decreased chemotaxis of blood neutrophils
in response to SDF-1 and elevated numbers of CXCR4high in
the blood after ACTH injection, nonaltered numbers of
CXCR4 neutrophils in the bone marrow were not expected.
Senescent neutrophils homing to the bone marrow are
CXCR4high (2, 19, 45). Phagocytosis by bone marrow macro-
phages is a mechanism of clearance of senescent and apoptotic
neutrophils, a process often associated with secretion of G-CSF
by macrophages to stimulate granulopoiesis (19, 45).
Therefore, the effect of in vivo ACTH treatment on the
phagocytosis of senescent/apoptotic neutrophils by macro-
phages was assessed ex vivo, and the levels of G-CSF were
measured in the supernatant of phagocytosing macrophages.
Neutrophils collected from ACTH- or vehicle-treated mice
were incubated for 18 h to become senescent, as confirmed by
the elevated percentage of CXCR4 and ANXAV staining on
the cell (Fig. 8, A and B). Nevertheless, the percentage of
CXCR4/ANXAV neutrophils and the levels of CXCR4 per
cell were reduced in senescent cells obtained from ACTH-
treated mice (Fig. 8, A–C). ACTH-senescent/apoptotic neutro-
phils were less phagocytosed by bone marrow macrophages
compared with vehicle-senescent/apoptotic neutrophils (Fig. 8,
D and E). Finally, levels of G-CSF were reduced in the
supernatant of macrophages phagocytosing senescent/apopto-
tic neutrophils collected from ACTH-treated animals (Fig. 8F).
DISCUSSION
This study reports, likely for the first time, that the blood
population of neutrophils after ACTH injection presents a
different profile of membrane receptor expression, a phenotype
associated with higher neutrophil interaction into the vessel
wall, but impaired subsequent migration into inflamed or
clearance tissues.
A direct action of ACTH on inflammation has been proposed
(21, 22, 38); nevertheless, the majority of data suggest a
fundamental role by its main mediators, the adrenal secreted
glucocorticoids, as rapid ACTH secretion and subsequent glu-
cocorticoid release in the circulation occurs during inflamma-
tion. In fact, here we show that ACTH injection elevates
plasma corticosterone levels and causes neutrophilia, which is
due, at least in part, to the elevated migration of mature
ANXA1high bone marrow neutrophils into the peripheral blood.
Because RU-38486 treated and ANXA1/ mice presented
neutrophilia, which was not altered by ACTH treatment, the
dependence on glucocorticoid interaction with the cytosolic
receptor and ANXA1 actions on ACTH-induced neutropilia
could not be established.
It has been shown that ANXA1high neutrophils are anti-
inflammatory cells, which do not migrate into inflamed tissues
(27, 47, 56). Because ACTH-recruited neutrophils in the blood
are ANXA1high, an inverse expression of ANXA1 and inflam-
matory proteins on the neutrophil membrane could be ex-
pected. Conversely, here we observed that circulating neutro-
phils from ACTH-treated mice are also CD62Lhigh, CD18high
CD49dhigh, and CXCR4high. CD62L mediates the neutrophil
rolling behavior, and CD18 and CD49d mediate the firm
adhesion of neutrophils to the vessel wall, which are the initial
and fundamental processes of neutrophil recruitment into in-
flamed tissues (31); also, CXCR4 is especially involved in the
homing of neutrophils into clearance tissues, including the
bone marrow (19). Intriguingly, enhanced leukocyte-endothe-
lial interactions in the post-capillary venules of the mesentery
network were observed after ACTH treatment. These data also
could not also be expected, as increased numbers of roller
neutrophils are reported in statuses like glucocorticoid defi-
ciency (16) or in ANXA1/ mice (9, 13). In both cases, the
increased rolling behavior is dependent on the elevated expres-
sion of CD62L on blood neutrophils (4, 5, 9). In fact, gluco-
corticoids, via ANXA1, detach neutrophils from the vessel
wall by inducing CD62L shedding from the membrane (9, 13,
26, 53). By showing that ACTH-treated mice present elevated
levels of circulating corticosterone and CD62Lhigh blood neu-
trophils and that ACTH injection reverted the elevated CD62L
B
C
A
Fig. 7. Effect of ACTH administration on chemotaxis induced by stromal-
derived factor-1 (SDF-1) and CXCR4 expression on neutrophils from bone
marrow. Balb/c mice were treated with ACTH (5 g/animal ip), and 4 h later
neutrophils were collected from the peripheral blood and bone marrow. A: in
vitro chemotaxis of neutrophils in response to SDF-1. B and C: %positive
CXCR4 cells (B) and CXCR4 expression (C) on neutrophils obtained from
bone marrow. Results are expressed as means  SE of 6 animals in each
group. Statistical analysis was performed using Student’s t-test and ANOVA,
followed by Tukey’s test. *P  0.05 vs. corresponding vehicle.
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levels in RU-38486-treated or ANXA1/ mice, we hypothe-
size that ACTH might have a direct action on CD62L expres-
sion. The role of glucocorticoids on CD18 and CD49d expres-
sion is controversial (3, 4, 16, 17, 56); in contrast, ANXA1
modulates CD18 expression, as shown by elevated and reduced
expression in neutrophils from ANXA1/ and in vitro WT
neutrophils treated with ANXA1, respectively (6, 35, 48).
Then, we showed that both CD18 and CD49d expression
following ACTH injection rely on cytosolic glucocorticoid
receptor activation, as well as ANXA1, thus describing a likely
genomic glucocorticoid action on in vivo integrin expression.
Together, the data presented here show that the profile of
membrane receptors on neutrophils after ACTH injection is
different from those observed during homeostasis, suggesting
that ACTH administration leads to a unique population of
circulating neutrophils, with an adhesion molecule phenotype
sufficient to allow release from the bone marrow, yet it pre-
serves an anti-inflammatory outcome. This hypothesis was
corroborated by the impaired neutrophil migration into the
inflamed tissue in ACTH-treated animals and by in vitro
neutrophil-reduced chemotaxis to fMLP and SDF-1. fMLP
binds to the FPR1, a G protein-coupled transmembrane recep-
tor that was found at lower levels in cells taken from ACTH-
treated mice. Although the reduced fMLP-induced chemotaxis
may be due to lower levels of the receptor, differences in
FPR-1 sensibility or the downstream intracellular activation
may not be excluded. In addition, the elevated membrane
expression of CXCR4 in the presence of a reduced chemotactic
response to SDF-1 by neutrophils from ACTH-treated mice
favors the hypothesis that these neutrophils may present altered
downstream activation and reactivity, and this may be stimulus
independent, indicating interference with fundamental pro-
cesses on chemotaxis that remains to be elucidated.
The equilibrium of granulopoiesis in the bone marrow is
maintained by the efficient clearance of CXCR4high senescent/
apoptotic neutrophils by local macrophages, which in turn
secrete G-CSF to enhance granulopoiesis (2, 19). Several
receptors on the apoptotic neutrophil membrane have been
proposed as signals for macrophage identification and phago-
cytosis (37), and phosphatidylserine (PS) exposure on the outer
membrane of apoptotic cells is the best-known determinant
(46). Here, we show that blood neutrophils from ACTH-treated
mice in a senescent profile presented lower levels of CXCR4
and ANXAV staining to quantify exposed PS on the outer
membrane and were less phagocytosed by bone marrow mac-
rophages. Together, these data show that ACTH injection
inhibits the apoptosis of neutrophils and their consequent
clearance by bone marrow macrophages. This effect may be
responsible for the normal number of CXCR4high neutrophils
in the bone marrow; even ACTH-injected mice presented
elevated numbers of blood CXCR4high neutrophils. The ACTH
effect may be indirect in view of the action of glucocorticoids,
as they enhance the lifespan of neutrophils (28, 52, 58). On the
other hand, ANXA1 is a proapoptotic protein in neutrophils by
virtue of activating caspase-3 and the inhibition of Mcl-1, ERK
1/2, and NF-
B-mediated survival signals (15a, 50, 57). These
apparently contradictory observations might reflect differences
in the functions of intracellular and extracellular ANXA1
during the apoptotic process, which may counterbalance the
glucocorticoid actions (15a).
Vehicle ACTH
ANXAV
C
X
C
R
4
Vehicle ACTH
100 101 102 103 104 105
10
0
10
1
10
2
10
3
10
4
10
5
100 101 102 103 104 105
10
0
10
1
10
2
10
3
10
4
10
5
A C
D
B
E F
Fig. 8. Effect of ACTH administration on neutrophil senescence process and on phagocytosis and granulocyte colony-stimulating factor (G-CSF) secretion by
bone marrow macrophage. Balb/c WT mice were treated with ACTH (5 g/animal ip) or vehicle. Four hours later, neutrophil were collected from the blood and
incubated in vitro for 18 h (5% CO2, 37°C). A: %neutrophils CXCR4ANXAV. B: illustrative flow cytometry dot plot of neutrophils CXCR4ANXAV. C:
CXCR4 expression. D: %phagocytosis of apoptotic neutrophils by bone marrow macrophages. E: representative images of phagocytosis of ACTH-senescent/
apoptotic neutrophils or vehicle-senescent/apoptotic neutrophils (gray arrowheads) by bone marrow macrophages (black arrowheads). F: G-CSF levels on
supernatant of in vitro phagocytosis assay. Results are expressed as means  SE of 6 animals in each group. Statistical analysis was performed using Student’s
t-test. *P  0.05, **P  0.01, and ***P  0.001 vs. vehicle.
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Recent data in the literature have broken some paradigms on
neutrophil trafficking in the body compartments and have
shown that different phenotypes of neutrophils exert functions
other than those related to the innate immune response (42–44,
51). Alterations in the profile and lifespan of neutrophils
contribute to the genesis of diseases and can be targeted as a
viable therapeutic approach for inflammatory diseases (34, 48).
Therefore, herein we expand our knowledge of the profile of
circulating neutrophils in stress conditions elicited by ACTH
injection and also highlight the influence of the cytosolic
glucocorticoid receptor and ANXA1 in some specific readouts
of this process. We conclude by proposing that neutrophil
plasticity and phenotype, with associated functional responses,
could be rapidly yet differently attained in stress settings, with
the ultimate outcome warying, whether in the presence or
absence of an inflammatory status. Future studies will be
essential to extend the molecular mechanisms and effectors of
this fascinating area of science that crosses endocrinology with
immunology and cell biology.
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